Last updated on February 2019

An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia

Brief description of study

An extension study of safety and tolerability of SEP-363856 in adult subjects with schizophrenia

Detailed Study Description

This is a 26 week, multiregional, open-label extension study designed to evaluate the long-term safety and tolerability of SEP-363856 for the treatment of subjects with schizophrenia who have completed the 4 week double-blind treatment phase of Study SEP361-201.

No statistical hypothesis tests will be performed.

Clinical Study Identifier: NCT02970929

Contact Investigators or Research Sites near you

Start Over

Woodland International research Group

Little Rock, AR United States

Kashinath Yadalam

Lake Charles, LA United States

Pillar Clinical Research, LLC

Dallas, TX United States

CNRI-Los Angeles, LLC

Pico Rivera, CA United States

Atlanta Center for Medical Research

Atlanta, GA United States

Sverdlov Regional Psychiatric Clinical Hospital

Ekaterinburg, Russian Federation

SPHI "City Mental Hospital #3 n.a. I.I.Skvortsov-Stepanov"

Saint-Petersburg, Russian Federation

City Psychiatric Hospital of St. Nikolay Chudotvorets

St. Petersburg, Russian Federation

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.